1 type in phase 2 clinical trials ('22) → 4 types ('27)
2 types (’22) → 15 types (’27)
progress rate 0% (‘22) → 100% (’27)
Registered resources 7,000 shares (’22) → 13,000 shares (’27)
Strengthening the role of the control tower for
rapid vaccine development and support
Establishing and managing strategies for national vaccine research and development
Establishing and operating a rapid vaccine development and support system to respond to crises
Securing key and new technologies for vaccine development
Establishing a vaccine library (advanced vaccine technology center) and discovering antigens rapidly (antigen design)
Establishing an immunological surveillance system to respond to pandemics (Korean PREMISE)
Strategic development of
public vaccines
Developing a new infectious disease vaccines
Developing a national vaccination vaccines
Developing a public security vaccines
Developing vaccines for unresolved infectious diseases
Strengthening support for the entire clinical and
non-clinical cycle of vaccine development
Strengthening non-clinical evaluation and support
Establishing and operating a (non-)clinical trial and sample analysis institute network
Strengthening vaccine-related clinical and immunological research
Strengthening the collection, management and utilization of pathogen resources
Strengthening the public- private international
cooperation system
Cooperation in establishing a rapid production system (cooperation with the Ministry of Trade, Industry and Energy (MOTIE))
Participation in establishing a non-clinical efficacy evaluation support system (cooperation with the Ministry of Science and ICT (MSIT)
Support for rapid approval work (cooperation with the Ministry of Food and Drug Safety (MFDS))
Expansion of joint global research (cooperation with international organizations/overseas institutions)
